Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26334
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Russell, K. J. | - |
dc.contributor.author | JANSSENS, Jaak | - |
dc.contributor.author | Dean, A. | - |
dc.contributor.author | Hernandez, A. | - |
dc.contributor.author | Voss, A. | - |
dc.date.accessioned | 2018-07-13T07:55:26Z | - |
dc.date.available | 2018-07-13T07:55:26Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | VALUE IN HEALTH, 20(9), p. A579-A579 (Art N° PMD42) | - |
dc.identifier.issn | 1098-3015 | - |
dc.identifier.uri | http://hdl.handle.net/1942/26334 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.rights | © 2017 Published by Elsevier Inc. | - |
dc.title | Treatment choices based on multiplatform profiling platform, unlike those with sequencing alone, do not cause a cost explosion in refractory cancer patients | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | A579 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | A579 | - |
dc.identifier.volume | 20 | - |
local.format.pages | 1 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Russell, K. J.; Hernandez, A.; Voss, A.] Caris Life Sci, Basel, Switzerland. [Janssens, J.] Univ Hasselt, Hasselt, Belgium. [Dean, A.] St John God Hosp, Subiaco, WA, Australia. | - |
local.publisher.place | NEW YORK | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
local.bibliographicCitation.artnr | PMD42 | - |
dc.identifier.doi | 10.1016/j.jval.2017.08.1026 | - |
dc.identifier.isi | 000413599901365 | - |
item.fulltext | With Fulltext | - |
item.contributor | Russell, K. J. | - |
item.contributor | JANSSENS, Jaak | - |
item.contributor | Dean, A. | - |
item.contributor | Hernandez, A. | - |
item.contributor | Voss, A. | - |
item.fullcitation | Russell, K. J.; JANSSENS, Jaak; Dean, A.; Hernandez, A. & Voss, A. (2017) Treatment choices based on multiplatform profiling platform, unlike those with sequencing alone, do not cause a cost explosion in refractory cancer patients. In: VALUE IN HEALTH, 20(9), p. A579-A579 (Art N° PMD42). | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 1098-3015 | - |
crisitem.journal.eissn | 1524-4733 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
russell 2.pdf Restricted Access | Published version | 58.92 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.